{
    "id": "dbpedia_4484_3",
    "rank": 40,
    "data": {
        "url": "https://finance.yahoo.com/quote/PHAT/",
        "read_more_link": "",
        "language": "en",
        "title": "Phathom Pharmaceuticals, Inc. (PHAT) Stock Price, News, Quote & History",
        "top_image": "https://pinhole.finance.yahoo.com/chart/PHAT/__screenshot",
        "meta_img": "https://pinhole.finance.yahoo.com/chart/PHAT/__screenshot",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "PHAT",
            "Phathom Pharmaceuticals",
            "Inc.",
            "PHAT stock chart",
            "Phathom Pharmaceuticals",
            "Inc. stock chart",
            "stock chart",
            "stocks",
            "quotes",
            "finance"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Find the latest Phathom Pharmaceuticals, Inc. (PHAT) stock quote, history, news and other vital information to help you with your stock trading and investing.",
        "meta_lang": "en",
        "meta_favicon": "https://s.yimg.com/cv/apiv2/finance/favicon_y19_16x16_custom.png",
        "meta_site_name": "",
        "canonical_link": "https://finance.yahoo.com/quote/PHAT/",
        "text": "NasdaqGS - Delayed Quote â€¢ USD\n\nPhathom Pharmaceuticals, Inc. (PHAT)\n\n12.17 +0.14 (+1.16%)\n\nAt close: August 13 at 4:00 PM EDT\n\n12.00 -0.17 (-1.40%)\n\nPre-Market: 8:00 AM EDT\n\nPrevious Close 12.03\n\nOpen 12.09\n\nBid 12.10 x 100\n\nAsk 12.21 x 400\n\nDay's Range 11.94 - 12.52\n\n52 Week Range 6.07 - 15.56\n\nVolume 484,479\n\nAvg. Volume 647,845\n\nMarket Cap (intraday) 725.259M\n\nBeta (5Y Monthly) 0.68\n\nPE Ratio (TTM) --\n\nEPS (TTM) -5.18\n\nEarnings Date Nov 7, 2024 - Nov 11, 2024\n\nForward Dividend & Yield --\n\nEx-Dividend Date --\n\n1y Target Est 23.00\n\nPhathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.\n\nwww.phathompharma.com\n\n452\n\nFull Time Employees\n\nDecember 31\n\nFiscal Year Ends\n\nHealthcare\n\nSector\n\nBiotechnology\n\nIndustry\n\nRecent News: PHAT\n\nView More\n\nAll SEC Filings\n\nCorporate Changes & Voting Matters\n\nPeriodic Financial Reports\n\nProxy Statements\n\nTender Offer/Acquisition Reports\n\nOffering Registrations\n\nPerformance Overview: PHAT\n\nTrailing total returns as of 8/13/2024, which may include dividends or other distributions. Benchmark is .\n\nYTD Return\n\nPHAT\n\n33.30%\n\nS&P 500\n\n13.93%\n\n1-Year Return\n\nPHAT\n\n21.94%\n\nS&P 500\n\n21.74%\n\n3-Year Return\n\nPHAT\n\n62.54%\n\nS&P 500\n\n21.83%\n\n5-Year Return\n\nPHAT\n\n45.91%\n\nS&P 500\n\n79.80%\n\nCompare To: PHAT\n\nSelect to analyze similar companies using key performance metrics; select up to 4 stocks.\n\n12.17\n\n+1.16%\n\nMkt Cap 725.259M\n\nIndustry Biotechnology\n\n26.73\n\n+8.31%\n\nMkt Cap 2.171B\n\nIndustry Biotechnology\n\n26.44\n\n+0.88%\n\nMkt Cap 1.006B\n\nIndustry Biotechnology\n\n37.34\n\n+0.78%\n\nMkt Cap 2.773B\n\nIndustry Biotechnology\n\n4.7600\n\n+4.39%\n\nMkt Cap 471.369M\n\nIndustry Biotechnology\n\n4.9300\n\n+11.29%\n\nMkt Cap 177.748M\n\nIndustry Biotechnology\n\n14.96\n\n+3.10%\n\nMkt Cap 630.027M\n\nIndustry Biotechnology\n\n9.95\n\n+4.85%\n\nMkt Cap 1.152B\n\nIndustry Biotechnology\n\n4.7100\n\n-0.84%\n\nMkt Cap 279.876M\n\nIndustry Biotechnology\n\n16.29\n\n-0.06%\n\nMkt Cap 944.439M\n\nIndustry Biotechnology\n\n45.11\n\n+0.83%\n\nMkt Cap 2.566B\n\nIndustry Biotechnology\n\nStatistics: PHAT\n\nView More\n\nValuation Measures\n\nMarket Cap\n\n725.26M\n\nEnterprise Value\n\n624.30M\n\nTrailing P/E\n\n--\n\nForward P/E\n\n--\n\nPEG Ratio (5yr expected)\n\n--\n\nPrice/Sales (ttm)\n\n70.92\n\nPrice/Book (mrq)\n\n--\n\nEnterprise Value/Revenue\n\n62.95\n\nEnterprise Value/EBITDA\n\n--\n\nFinancial Highlights\n\nProfitability and Income Statement\n\nProfit Margin\n\n0.00%\n\nReturn on Assets (ttm)\n\n-54.07%\n\nReturn on Equity (ttm)\n\n--\n\nRevenue (ttm)\n\n9.92M\n\nNet Income Avi to Common (ttm)\n\n-297.11M\n\nDiluted EPS (ttm)\n\n-5.18\n\nBalance Sheet and Cash Flow\n\nTotal Cash (mrq)\n\n276.24M\n\nTotal Debt/Equity (mrq)\n\n--\n\nLevered Free Cash Flow (ttm)\n\n-154.15M\n\nResearch Analysis: PHAT\n\nView More\n\nPeople Also Watch\n\nYMAB Y-mAbs Therapeutics, Inc.\n\n10.82\n\n+8.74%\n\nSTOK Stoke Therapeutics, Inc.\n\n14.17\n\n-1.90%\n\nORIC ORIC Pharmaceuticals, Inc.\n\n8.84\n\n+6.76%\n\nMIRM Mirum Pharmaceuticals, Inc.\n\n41.09\n\n-8.16%\n\nREPL Replimune Group, Inc.\n\n9.73\n\n+1.88%\n\nETNB 89bio, Inc.\n\n8.02\n\n+2.56%\n\nARQT Arcutis Biotherapeutics, Inc.\n\n9.95\n\n+4.85%\n\nCABA Cabaletta Bio, Inc.\n\n4.5600\n\n+4.11%\n\nRAPT RAPT Therapeutics, Inc.\n\n2.4700\n\n+0.82%\n\nIGMS IGM Biosciences, Inc.\n\n8.88\n\n+0.57%\n\nSRRK Scholar Rock Holding Corporation\n\n9.71\n\n+2.43%\n\nAKRO Akero Therapeutics, Inc.\n\n24.77\n\n+2.40%\n\nSWTX SpringWorks Therapeutics, Inc.\n\n37.34\n\n+0.78%\n\nKROS Keros Therapeutics, Inc.\n\n44.62\n\n-0.49%\n\nCRNX Crinetics Pharmaceuticals, Inc.\n\n50.33\n\n+1.53%\n\nIDYA IDEAYA Biosciences, Inc.\n\n38.18\n\n+1.60%"
    }
}